Point72 Asset Management L.P. Buys 9,387 Shares of Repligen Co. (NASDAQ:RGEN)

Point72 Asset Management L.P. boosted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 324,434 shares of the biotechnology company's stock after acquiring an additional 9,387 shares during the period. Point72 Asset Management L.P. owned 0.58% of Repligen worth $48,282,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in RGEN. Andra AP fonden purchased a new stake in shares of Repligen during the second quarter worth $25,000. International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter valued at $33,000. UMB Bank n.a. lifted its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. boosted its stake in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 127 shares during the period. Finally, nVerses Capital LLC purchased a new position in Repligen during the 3rd quarter valued at about $45,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of a number of analyst reports. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Finally, Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Price Performance

NASDAQ RGEN traded down $6.83 during trading hours on Thursday, reaching $142.26. 443,658 shares of the stock traded hands, compared to its average volume of 661,336. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a 50 day simple moving average of $141.38 and a two-hundred day simple moving average of $142.15. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a market cap of $7.97 billion, a price-to-earnings ratio of -384.48, a price-to-earnings-growth ratio of 4.47 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $0.23 EPS. On average, analysts predict that Repligen Co. will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.